Sector News

Eli Lilly to buy Boehringer Ingelheim pet vaccines portolio

October 11, 2016
Life sciences

Eli Lilly & Co. is buying Boehringer Ingelheim Vetmedica Inc.’s U.S. pet vaccines portfolio for $885 million as it continues to grow its animal unit.

Lilly’s animal-health subsidiary, Elanco U.S., is buying the portfolio of cat, dog and rabies vaccines, which includes drugs to prevent Lyme disease and Canine Infectious Respiratory Disease.

“We understand the unique bond that owners share with pets and are committed to helping those pets live longer, healthier lives,” said Elanco Animal Health President Jeff Simmons.

The deal also includes a Fort Dodge, Iowa, manufacturing and research site, with an on-site veterinary research center, and several potential drugs in the research pipeline.

Lilly has expanded its animal medicine division in recent years, buying Novartis AG’s animal-health business for $5.4 billion in early 2015. The animal health unit brought in $3.18 billion in revenue for Lilly in 2015.

The move is required for an asset swap with French pharmaceutical company Sanofi to move forward. Sanofi is exchanging its animal health business Merial for Boehringer Ingelheim’s consumer health-care unit and cash.

The deal is expected to close by early 2017 and subject to approval by the Federal Trade Commission, antitrust regulators and the closing of the Sanofi asset swap.

Lilly expects the deal to add to adjusted earnings in 2018 and to as-reported earnings in 2019.

By Austen Hufford

Source: Wall Street Journal

comments closed

Related News

May 26, 2024

From pharma to food: Vitafoods 2024 highlights

Life sciences

Beyond the vibrant displays and insightful discussions at Vitafoods 2024 stood the backdrop of a rapidly expanding nutraceutical market. With consumers increasingly seeking preventive healthcare solutions and natural alternatives to traditional medicine, the global nutraceutical industry has witnessed remarkable growth in recent years.

May 26, 2024

Genmab completes acquisition of ProfoundBio

Life sciences

Genmab has completed its $1.8 billion acquisition of ProfoundBio, a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADC)s and ADC technologies for the treatment of cancers.

May 26, 2024

Merck to acquire life science company Mirus Bio

Life sciences

Merck has agreed to acquire US life sciences company Mirus Bio for $600 million (around €550 million) from Gamma Biosciences, a life sciences platform established by global investment firm KKR. Based in Madison, Wisconsin, Mirus Bio is a specialist in the development and commercialization of transfection reagents.

How can we help you?

We're easy to reach